2022 World Conference on Lung Cancer (ePosters)-EP08.01-018. Patterns of Failure in Metastatic NSCLC Treated with First Line Pembrolizumab and Impact of Local Therapy in Patients with Oligoprogression

EP08.01-018. Patterns of Failure in Metastatic NSCLC Treated with First Line Pembrolizumab and Impact of Local Therapy in Patients with Oligoprogression

Back to course

Pdf Summary

This study aimed to analyze the patterns of failure (POF) in metastatic non-small cell lung cancer (NSCLC) patients treated with first-line pembrolizumab and investigate the impact of local therapy on patients with oligoprogression (OPD). The study included consecutive treatment-naïve patients with mNSCLC who received pembrolizumab alone or in combination with chemotherapy between 2015 and 2020. <br /><br />The results showed that patients with OPD, defined as disease growth in three or fewer anatomic sites, had better overall survival compared to those with polyprogression. Additionally, patients with OPD who received local therapy had significantly longer overall survival compared to those who changed systemic therapies. The study suggests that local ablative therapy may allow the continuation of effective immunotherapy in patients with limited disease progression. <br /><br />The analysis of POF revealed that the most common pattern of failure was a combination of existing and new lesions, followed by new lesions alone. In terms of anatomical distribution, distant-only progression was the most common, followed by combination progression. <br /><br />The study also provided information on patient demographics, including age, gender, histology, PD-L1 status, and metastatic burden at diagnosis. The median progression-free survival was 9.1 months, and the median overall survival was 23.1 months. <br /><br />The study concludes that oligoprogression is common in mNSCLC patients treated with immunotherapy and that local therapy may improve overall survival in this population. Randomized prospective studies are needed to further investigate the benefits of local therapy while continuing checkpoint inhibitors.

Asset Subtitle

Cole Friedes

Meta Tag

Speaker Cole Friedes

Topic Metastatic Non-small Cell Lung Cancer - Immunotherapy

Keywords

patterns of failure

metastatic non-small cell lung cancer

NSCLC

pembrolizumab

local therapy

oligoprogression

overall survival

systemic therapies

local ablative therapy

immunotherapy